Aptose Biosciences Inc.
APS.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -21.12M | -21.33M | -25.43M | -35.80M | -40.29M |
| Total Depreciation and Amortization | 394.00K | 394.00K | 404.00K | 417.00K | 432.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 91.00K | 168.00K | 532.00K | 1.62M | 2.20M |
| Change in Net Operating Assets | -6.54M | -6.24M | -11.48M | -3.41M | 330.00K |
| Cash from Operations | -27.17M | -27.01M | -35.98M | -37.18M | -37.34M |
| Capital Expenditure | -5.00K | -5.00K | -5.00K | 0.00 | 0.00 |
| Sale of Property, Plant, and Equipment | 5.00K | 22.00K | 23.00K | 18.00K | 18.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 1.99M | 0.00 | 1.94M | 14.89M |
| Cash from Investing | 0.00 | 2.01M | 18.00K | 1.96M | 14.91M |
| Total Debt Issued | 12.60M | 10.00M | 10.00M | -- | -- |
| Total Debt Repaid | -100.00K | -- | -- | -- | -- |
| Issuance of Common Stock | 10.84M | 15.77M | 26.79M | 27.63M | 22.53M |
| Repurchase of Common Stock | -3.35M | -3.35M | -3.35M | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 156.00K | -21.00K | -21.00K | -167.00K | -172.00K |
| Cash from Financing | 20.14M | 22.40M | 33.41M | 27.46M | 22.36M |
| Foreign Exchange rate Adjustments | 0.00 | 1.00K | 0.00 | -1.00K | 0.00 |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7.03M | -2.60M | -2.55M | -7.76M | -70.00K |